Clinical Trials Directory

Trials / Completed

CompletedNCT02033382

Biomarkers in First Episode Schizophrenia

Status
Completed
Phase
Study type
Observational
Enrollment
165 (actual)
Sponsor
NYU Langone Health · Academic / Other
Sex
All
Age
16 Years – 40 Years
Healthy volunteers
Accepted

Summary

This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after initiation of antipsychotic medication

Detailed description

It is currently unknown whether deterioration early in the course of psychotic illness represents medication toxicity or the natural course of the illness. The study will help clarify this issue in observing 70 schizophrenic patients before and after they are prescribed an antipsychotic via standard of care. In addition, schizophrenia is a heterogeneous disorder and a putative brain-derived neurotrophic factor (BDNF) deficit, while possibly a common pathway, may not fully capture the biological diversity-the supplemental biomarkers will allow us to perform a more comprehensive assessment of factors contributing to clinical course. Taken together analysis of these biomarkers in relation to clinical course and in relation to healthy subjects will inform us about biological mechanisms contributing to illness onset, effects of antipsychotic medication on these mechanisms, and the predictive value of the biomarkers for clinical course. This information will provide the foundation for future early intervention trials targeting biological mechanisms utilizing a personalized medicine approach. The baseline visit for 70 schizophrenic patients and 70 healthy age and gender matched controls consists of structural and functional MRI in addition to a blood draw for biomarkers including BDNF, inflammation markers, DNA, oxidative stress, and folate status and additionally a salivary cortisol sample collection. Biomarkers and imaging will be repeated after 8 weeks of antipsychotic treatment in patients.

Conditions

Timeline

Start date
2012-07-01
Primary completion
2014-12-01
Completion
2014-12-01
First posted
2014-01-10
Last updated
2021-01-14
Results posted
2021-01-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02033382. Inclusion in this directory is not an endorsement.